BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The BioCalendar
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20220427T160000
DTEND;TZID=UTC:20220427T190000
DTSTAMP:20260514T015844
CREATED:20220404T095332Z
LAST-MODIFIED:20220517T072215Z
UID:2680-1651075200-1651086000@thebiocalendar.com
SUMMARY:Virtual BioXchange April 27
DESCRIPTION:Miss being able to network with colleagues in the life science industry? We have you covered with the best virtual networking experience through Grapevine Network’s networking platform. Connect with life science colleagues from all over the world. \nBioXchange has gone virtual to allow the best online opportunity to interact with individuals from throughout the life science industry. The event will be hosted on Grapevine Network’s platform which provides an amazing experience that allows attendees the freedom to navigate between different group discussions within an interactive chatroom environment. The platform provides the closest experience to a live networking experience. \nParticipants are welcome to join the event at any point of time. The event is subject to run later than the posted end time as the room will stay open as long as people are actively engaged within the chat room. \n***Event is expected to sell out and NOT ALL RVSPS ARE GUARANTEED ENTRY into the event due to the limited attendee capacity offered on the platform.
URL:https://thebiocalendar.com/event/virtual-bioxchange-7/
LOCATION:PA
ATTACH;FMTTYPE=image/gif:https://thebiocalendar.com/wp-content/uploads/2022/04/Purple-Zodiac-Sign-Animated-Presentation-13-1.gif
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220427T140000
DTEND;TZID=UTC:20220427T150000
DTSTAMP:20260514T015844
CREATED:20220425T214108Z
LAST-MODIFIED:20220425T214110Z
UID:2744-1651068000-1651071600@thebiocalendar.com
SUMMARY:Halloran Speaker Series | The Future of RBQM and Customized Key Risk Indicator Libraries: How Small Companies Can Take Big Steps to Reduce Risk and Trial Oversight
DESCRIPTION:Identifying the key risks to be monitored in a clinical study is critical for a successful implementation of a Risk-Based Quality Management process (RBQM)\, and even more\, to the overall success of the clinical trial. Identifying the right Key Risk Indicators (KRIs) is also of utmost importance because they are the risk indicators that enable clinical study teams to proactively make informed decisions along the way. To put it simply\, a study team needs the right KRIs to actively monitor the trial’s risks. \nWe’ve witnessed many small biopharma companies wonder if there are different ways to identify and manage KRIs for their trial\, particularly\, because many face the challenge of not having enough data to inform KRI selections from the onset. Some companies just don’t have that data and insight\, so they often rely on a KRI library from their vendors. \nAs we zoom out from those observations\, we want to share our insights with you on the future of RBQM that will be helpful especially to smaller companies\, particularly around the following questions: \nIf you don’t have enough data to inform decisions on KRIs\, where do you start?\nHow do you implement a risk-based quality management process to inform KRIs?\nShould companies have a library of KRIs to utilize from the onset?\nWhat does it look like to overdo it vs. underdo it and why does this viewpoint matter?\nHow should companies partner with their vendors on KRIs?\nHow should you develop KRIs if you outsource your studies to CROs?\nWhen should you start developing KRIs and your RBQM processes?\nWhat does the future of customized risk management look like? \nWe invite you to this conversation on Thursday\, April 27th from 2-3 pm ET on “The Future of RBQM and Customized Key Risk Indicator Libraries How Small Companies Can Take Big Steps to Reduce Risk and Provide Trial Oversight” led by Sheila Gwizdak\, VP of Quality at Halloran Consulting Group\, and members of the Organizational Quality Solutions and Clinical teams during our Halloran-hosted Speaker Series.
URL:https://thebiocalendar.com/event/halloran-speaker-series-the-future-of-rbqm-and-customized-key-risk-indicator-libraries-how-small-companies-can-take-big-steps-to-reduce-risk-and-trial-oversight/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2022/04/Speaker-Series-4.27.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220426T100000
DTEND;TZID=UTC:20220426T110000
DTSTAMP:20260514T015844
CREATED:20220415T180700Z
LAST-MODIFIED:20220415T180700Z
UID:2728-1650967200-1650970800@thebiocalendar.com
SUMMARY:Expediting Access to Novel/Medicinal Products in the US and EU
DESCRIPTION:Regulatory Pathways Available to Speed Development and Approval\n \nVeristat and TOPRA will be hosting a webinar on the topic of: \nExpediting Access to Novel/Medicinal Products\nin the United States and Europe\nTuesday\, April 26\, 2022\n10:00 AM – 11:00 AM EDT (15:00 -16:00 BST) \n\nWhat  You Will Learn\nBringing novel medicinal products to market is a long\, complex\, and expensive process which requires drug developers to balance the need for rigorous testing with the goal of getting medicines quickly to patients who need them. To this end\, both US and European regulatory agencies have developed expedited pathways to accelerate the approval process for therapies that treat serious conditions and unmet medical needs.   \nVeristat Regulatory experts will discuss how developers of such therapies can utilize some or multiple programs/pathways to accelerate approval in the US and Europe. This webcast will highlight the requirements\, benefits\, and procedures for following US pathways: Accelerated Approval\, Breakthrough Therapy Designation\, Fast Track\, and Priority Review Designation. Then we will examine the similarities and differences to the EU pathways: Accelerated Assessment\, Conditional Marketing Application (CMA)\, and Priority Medicines Scheme (PRIME). The discussion will culminate with real-world examples and success stories.  \nOur experts will share their experience\, successes\, and lessons learned on how to: \n\nUnderstand when and how to apply for the following expedited pathways with FDA and European Regulatory Authorities:\n\n\n Breakthrough Therapy (BT)\n Fast Track (FT)\n Priority Review\n Accelerated Approval\n Accelerated Assessment\n Conditional Marketing Authorization (CMA)\n PRIME \n\n\n Consider real-world examples of increased efficiency with submitting pathways requests with FDA and EMA independently and simultaneously
URL:https://thebiocalendar.com/event/expediting-access-to-novel-medicinal-products-in-the-us-and-eu/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220428
DTSTAMP:20260514T015844
CREATED:20220319T053531Z
LAST-MODIFIED:20220319T200054Z
UID:2662-1650931200-1651103999@thebiocalendar.com
SUMMARY:Charles River's 6th Annual Viral Safety and Viral Clearance Summit
DESCRIPTION:Join us for a two-day event uniting experts on viral safety and viral clearance taking place at the Hyatt Centric Fisherman’s Wharf in San Francisco\, CA. Gain insight from expert regulatory authorities\, academic researchers\, and industry leaders who are defining the way we evaluate biologics\, vaccines\, and advanced therapeutic medicinal products (ATMPs). Discover new technologies\, learn best practices\, and achieve a solid understanding for designing an efficient manufacturing process.
URL:https://thebiocalendar.com/event/charles-rivers-6th-annual-viral-safety-and-viral-clearance-summit/
LOCATION:PA
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2022/03/Viral-Safety-and-Viral-Clearance-Summit-Image.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220428
DTSTAMP:20260514T015844
CREATED:20211106T202200Z
LAST-MODIFIED:20211106T202200Z
UID:2374-1650931200-1651103999@thebiocalendar.com
SUMMARY:BioTrinity 2022
DESCRIPTION:BioTrinity 2022: Catalysing Growth in the Life Sciences Industry \nBioTrinity is a proven\, must-attend London conference\, that catalyses growth and supports in-person re-engagement across the life sciences industry. \nThe event is attended by an ever-evolving audience of early stage and emerging life sciences R&D Companies\, investors\, large pharma\, and other valued partners throughout the life sciences ecosystem. The conference features a focused\, relevant\, and stimulating programme\, led by great speakers\, who bring their knowledge\, expertise\, and vision to the fore in exciting\, high-quality sessions. \nInteracting with new companies each year is something we believe to be a critical attribute of a successful conference and we work hard to ensure that a substantial and fresh line-up of investable opportunities and collaboration possibilities are showcased.
URL:https://thebiocalendar.com/event/biotrinity-2022/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220425
DTEND;VALUE=DATE:20220427
DTSTAMP:20260514T015844
CREATED:20220415T175953Z
LAST-MODIFIED:20220415T175953Z
UID:2727-1650844800-1651017599@thebiocalendar.com
SUMMARY:Stanford Drug Discovery Symposium (SDDS)
DESCRIPTION:Welcome to 2022 Stanford Drug Discovery Symposium. This symposium provides a valuable and important platform for inspiring interdisciplinary exchange at the forefront of drug research and will support a fantastic networking experience. It provides a great resource for researchers\, pharmaceutical companies\, investment groups\, and those in the wider biomedical community interested in discovering new drugs and improving patient care. We look forward to an exciting two days of talks and discussion. \n\n\n\n\n\n\n\n\n\n— Joseph C. Wu\, MD\, PhD | Director\, Cardiovascular Institute
URL:https://thebiocalendar.com/event/stanford-drug-discovery-symposium-sdds/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220421T170000
DTEND;TZID=UTC:20220421T183000
DTSTAMP:20260514T015844
CREATED:20220315T195718Z
LAST-MODIFIED:20220315T195718Z
UID:2659-1650560400-1650565800@thebiocalendar.com
SUMMARY:Cell & Gene Therapies Annual Meeting
DESCRIPTION:Cell & Gene therapies are the latest revolution in medicine manufacturing. Unlike small molecules or traditional biotech products\, these therapies introduce cells and genes into a patient to treat the underlying cause of a disease—they are living medicines! \nWhether you are producing biologic drug substance\, conducting sterile fill-finish operations\, or entering into cell and gene therapy\, this meeting will provide the latest information to help your organization have the knowledge and agility needed to meet the needs of the patients we serve. \nOur esteemed speakers will share their experience and recent advancements on Cell & Gene Therapies\, with insights from clinical trials to manufacturing and commercialization aspects of the drugs of the future. \nJoin this interactive virtual session\, to connect with key players\, learning their latest strategies\, challenges and vision for the future of Cell & Gene Therapies.
URL:https://thebiocalendar.com/event/cell-gene-therapies-annual-meeting-2/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220421T130000
DTEND;TZID=UTC:20220421T143000
DTSTAMP:20260514T015844
CREATED:20220413T182326Z
LAST-MODIFIED:20220413T182326Z
UID:2707-1650546000-1650551400@thebiocalendar.com
SUMMARY:The Investor Mindset & How to Cater your Pitch in the Current Economy
DESCRIPTION:How does the current economic environment affect the biotech venture investor mindset and outlook? How should you position your company and cater your pitch for success? Join our expert panel for an informative and eye-opening webinar. \nSpeakers:\n—Mike Powell\, Executive Partner\, Omega Funds\n—Shobha Parthasarathi\, Vice President\, Xontogeny\n—Kanad Das\, Investment Director\, Boehringer Ingelheim Venture Fund\n—Ed Saltzman\, Head\, Biotech Strategy\, Lumanity (moderator)
URL:https://thebiocalendar.com/event/the-investor-mindset-how-to-cater-your-pitch-in-the-current-economy/
LOCATION:PA
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2022/04/37eb5188-987a-453a-85b2-99f5d55cbe36.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220420T123000
DTEND;TZID=UTC:20220420T133000
DTSTAMP:20260514T015844
CREATED:20220413T185858Z
LAST-MODIFIED:20220413T185858Z
UID:2721-1650457800-1650461400@thebiocalendar.com
SUMMARY:Biotech Market Opportunities Abroad: Partnering with the U.S. Commercial Service in the Bay Area
DESCRIPTION:Join Biocom California and the U.S. Commercial Service of the U.S. Department of Commerce for a live webinar about biotech expansion opportunities in Germany and the U.K. The panel will discuss how the CS can assist Bay Area biotechs with resources\, USG assistance\, and inroads to the German and U.K. markets. Featured speakers from Bay Area-based Gritstone Bio and Invitae will share lessons learned when expanding abroad. Commercial Specialists from Germany and the U.K. will also be present to take questions from members. \nSpeakers: \n\nAndrew Allen\, CEO\, Gritstone Bio\nTony Jones\, CEO\, One Nucleus\nDr. Gregor Kemper\, Senior Manager Medical Biotechnology\, Germany Trade & Invest\nMaria-Elena Rivero\, U.S. Commercial Service\, San Francisco\, Biotech\nVishal Sikri\, President\, Oncology\, Invitae
URL:https://thebiocalendar.com/event/biotech-market-opportunities-abroad-partnering-with-the-u-s-commercial-service-in-the-bay-area/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220420
DTEND;VALUE=DATE:20220423
DTSTAMP:20260514T015844
CREATED:20211106T201906Z
LAST-MODIFIED:20211106T201906Z
UID:2371-1650412800-1650671999@thebiocalendar.com
SUMMARY:The Cell & Gene Meeting on the Mediterranean
DESCRIPTION:The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the ATMP community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector\, this program features expert-led panels\, extensive one-on-one partnering capabilities\, exclusive networking opportunities\, and 80+ dedicated presentations by leading publicly traded and privately held companies in the space. Join ARM for Europe’s premier conference for advanced therapies.
URL:https://thebiocalendar.com/event/the-cell-gene-meeting-on-the-mediterranean/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220419T190000
DTEND;TZID=UTC:20220419T213000
DTSTAMP:20260514T015844
CREATED:20220413T184929Z
LAST-MODIFIED:20220413T184929Z
UID:2711-1650394800-1650403800@thebiocalendar.com
SUMMARY:How to Get an Edge Over Your Competitors to Win the Product Development Race
DESCRIPTION:Over the years\, we have witnessed unprecedented success\, advancement\, and investment in biotech R&D. As a result\, R&D competition is as fierce as it has ever been. But many companies are only focused on their progress of assets and portfolios and that inward-facing diligence typically does not incorporate a rational\, pragmatic\, and unbiased view of the overall competition. Rather\, an extensive overall review increases knowledge about what an organization is up against and informs strategic decisions on how to win. This is the value of competitive intelligence. \nPlease join us to understand how young biotech companies are using competitive intelligence to design smart and meaningful clinical trials\, differentiate their therapy\, and improve the likelihood of regulatory success across different geographical locations. \nMeet Our Speakers: \n \nSarah Boyce\, President & CEO\, Avidity Biosciences \n \nDaniel Corey\, M.D.\, Founder & CSO\, CERo Therapeutics \n \nChris Kreuger\, CBO\, Ventyx Bio \n \nErika Dahl\, Consultant\, Strategy & Program Leadership\, Halloran Consulting Group \n \nAnmol Grover\, Associate Principal Consultant\, Halloran Consulting Group (Moderator) \nThe panel will discuss the following topics: \n\nIdentifying the importance of competitive intelligence and why it’s essential to an organization and their investors\nHow to decide the best timing to gather this insight – when is it too early?\nHow to streamline the most essential competitive intelligence arenas\, such as regulatory precedents\, competitor information\, and clinical operation parameters?\nHow to identify the key competitive intelligence sources?\nHow to maximize all that information and use that for a competitive development strategy to differentiate your organization?\nWhen to conduct competitive intelligence internally vs. externally and how to establish that structure\, support system\, and key objectives?\n\nSponsored by: \n \n*Halloran Consulting Group’s Strategy and Program Leadership group has assisted clients in identifying the unmet need\, the current treatment landscape\, approved and to-be approved therapies\, and interventions in clinical and preclinical stages of development. These insights dovetailed with tailored development strategy\, has helped clients to differentiate their drug from competitors and carve a niche market within the dense treatment landscape. 
URL:https://thebiocalendar.com/event/how-to-get-an-edge-over-your-competitors-to-win-the-product-development-race/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220418
DTEND;VALUE=DATE:20220422
DTSTAMP:20260514T015844
CREATED:20211106T202047Z
LAST-MODIFIED:20220121T085724Z
UID:2372-1650240000-1650585599@thebiocalendar.com
SUMMARY:Drug Discovery Chemistry
DESCRIPTION:Focused on discovery and optimization challenges of small molecule drug candidates\, Drug Discovery Chemistry is a dynamic in-person and online event for medicinal and biophysical chemists working in pharma\, biotech\, and academia. Nearly 800 attendees participated virtually this year\, with 71% of delegates from pharma/biotech and 16% from academia. 60% of attendees were scientists/technologists and 22% were executives/directors. \nSpeakers from the following have already confirmed their participation for April’s event\, which will be available in-person to vaccinated attendees only: Amgen\, Astex Pharmaceuticals\, AstraZeneca\, Aurigene Discovery Technologies\, Bayer Pharmaceuticals\, Baylor College of Medicine\, Biogen\, Bristol Myers Squibb\, Dana Farber Cancer Institute\, ETH Zurich\, Fred Hutchinson Cancer Research Center\, Genentech\, Insilico Medicine\, Merck\, Novartis\, Pfizer\, Progenra\, Scripps Research Institute\, St. Jude Children’s Research Hospital\, and many more. \nLimited speaking opportunities are available. If you would like to be considered for a podium presentation\, please submit a speaker proposal ASAP. As a reminder\, attendees still have on-demand access to watch presentations\, listen to Q&A panel discussions\, review posters\, and much more.
URL:https://thebiocalendar.com/event/drug-discovery-chemistry/
LOCATION:PA
CATEGORIES:Featured
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2021/11/dch22-conf-header-logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220413T170000
DTEND;TZID=UTC:20220413T190000
DTSTAMP:20260514T015844
CREATED:20220404T215147Z
LAST-MODIFIED:20220404T215147Z
UID:2683-1649869200-1649876400@thebiocalendar.com
SUMMARY:Bio in the Brewery
DESCRIPTION:California Life Sciences invites you to join us and our Southern California members to connect over award-winning beer\, appetizers and patio games at Ballast Point’s largest brewery and outdoor restaurant. Don’t miss the opportunity to connect with San Diego’s life science community. \nThis event is closed to service provider companies that are not members of California Life Sciences. To become a member\, click here.
URL:https://thebiocalendar.com/event/bio-in-the-brewery/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220412T000000
DTEND;TZID=UTC:20220414T235900
DTSTAMP:20260514T015844
CREATED:20220212T015234Z
LAST-MODIFIED:20220212T015308Z
UID:2602-1649721600-1649980740@thebiocalendar.com
SUMMARY:MASS East
DESCRIPTION:The Fierce Medical Affairs Strategic Summit is an educational community that provides a holistic view of medical affairs\, allowing organizations to develop a unified scientific voice. Join us and interact with medical affairs colleagues as we tackle different stages of the product lifecycle\, from evidence generation to Phase 4 studies\, to ensure both internal and external messaging are being communicated effectively to thought leaders\, through increased and compliant medical communication strategies.
URL:https://thebiocalendar.com/event/mass-east/
LOCATION:PA
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2022/02/MASS22_300x250.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220412T000000
DTEND;TZID=UTC:20220414T235900
DTSTAMP:20260514T015844
CREATED:20220212T014934Z
LAST-MODIFIED:20220212T015437Z
UID:2600-1649721600-1649980740@thebiocalendar.com
SUMMARY:Promotional Review Committee Compliance and Best  Practices Summit (PRC) East
DESCRIPTION:The Fierce Promotional Review Committee Compliance and Best Practices Summit will allow cross-functional professionals involved in promotional review boards across large pharma and biotech organizations to learn how to collaborate more effectively and ensure quicker reviews of advertising materials\, while staying compliant.
URL:https://thebiocalendar.com/event/promotional-review-committee-compliance-and-best-practices-summit-prc-east/
LOCATION:PA
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2022/02/PRC22_300x250.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220412
DTEND;VALUE=DATE:20220415
DTSTAMP:20260514T015844
CREATED:20211103T060835Z
LAST-MODIFIED:20220103T193734Z
UID:2355-1649721600-1649980799@thebiocalendar.com
SUMMARY:SynBioBeta: Global Synthetic Biology Conference
DESCRIPTION:Live and in person *NEW DATES*: APRIL 12-14\, 2022 @ the Oakland Marriott City Center. \nAfter TWO years of digital meetings\, we’re bringing synthetic biology’s leading community of innovators\, investors\, engineers\,… \nBecause Being in the Same Room is Better Than Being on the Same Zoom\, and we really miss you!
URL:https://thebiocalendar.com/event/synbiobeta-global-synthetic-biology-conference/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220410
DTEND;VALUE=DATE:20220414
DTSTAMP:20260514T015844
CREATED:20220128T235604Z
LAST-MODIFIED:20220128T235604Z
UID:2531-1649548800-1649894399@thebiocalendar.com
SUMMARY:Society for Inherited Metabolic Disorders (SIMD) 43rd Annual Meeting
DESCRIPTION:The SIMD meeting will be held April 10-13 2022 at the Rosen Shingle Creek Resort in Orlando\, Florida.\nNote: Safety protocols will be in effect\, and attendees will be required to verify Covid-19 vaccination (see General Information). \nThe meeting will feature sessions on: \n\nThe Continuum of Hope: a session on n=1 treatments for inborn errors of metabolism\nIEMs as secondary findings\nBiomarkers:  Not everything worthwhile can be measured (and not everything measured is worthwhile)\nUnknowns and Challenging Metabolic Cases\nCulturally Competent Care\nCutting Edge Treatment Modalities\nBest of the submitted abstracts talks\nTravel award winner presentations\nPresentations from the 2021 Shapira award winner and the JSIMD Young Investigator award winner.\nPosters will be displayed for the entire meeting allowing their view during breaks and an attended Poster session\nExhibits from top IEM companies\nSatellite symposium on The Evolving Treatment and Management Landscape for Patients with Long-Chain Fatty Acid Oxidation Disorders.
URL:https://thebiocalendar.com/event/society-for-inherited-metabolic-disorders-simd-43rd-annual-meeting/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220408
DTEND;VALUE=DATE:20220414
DTSTAMP:20260514T015844
CREATED:20211106T201708Z
LAST-MODIFIED:20211106T201708Z
UID:2370-1649376000-1649894399@thebiocalendar.com
SUMMARY:AACR Annual Meeting 2022
DESCRIPTION:The AACR Annual Meeting is the focal point of the cancer research community\, where scientists\, clinicians\, other health care professionals\, survivors\, patients\, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology\, translational\, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world. \n\n\n\nContinuing Medical Education Activity AMA PRA Category 1 CreditsTM available \n\n\n\n\n#AACR22
URL:https://thebiocalendar.com/event/aacr-annual-meeting-2022/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220404
DTEND;VALUE=DATE:20220406
DTSTAMP:20260514T015844
CREATED:20220304T204622Z
LAST-MODIFIED:20220304T204622Z
UID:2640-1649030400-1649203199@thebiocalendar.com
SUMMARY:Chief Medical Officer Summit 360°
DESCRIPTION:The Chief Medical Officer Summit 360° is celebrating its 10th year. The CMO Summit 360® is the forum for Biotech CMOs to connect with peers and develop the skills needed to succeed in their current CMO role and beyond. This is the conference to network with other biotech CMOs across indications\, company stages and geographic locations. The CMO Summit attracts the largest gathering of physicians in biotech to address the unique challenges associated with directing and managing R&D functions often with limited resources\, while raising capital and strategizing for growth and appropriate exits.
URL:https://thebiocalendar.com/event/chief-medical-officer-summit-360/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2022/03/CMO-10-annual-banner-2022.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220402
DTEND;VALUE=DATE:20220408
DTSTAMP:20260514T015844
CREATED:20211106T201503Z
LAST-MODIFIED:20211106T201503Z
UID:2369-1648857600-1649375999@thebiocalendar.com
SUMMARY:2022 AAN Annual Meeting
DESCRIPTION:2022 ANNUAL MEETING\nThe 2022 AAN Annual Meeting is back in person—with the addition of a distinct convenient virtual option\, too! In both meetings\, find exclusive neurology science and education perfectly catered to neurology professionals worldwide—from those exploring an interest in neurology to those continually advancing in an established career. See pricing information and register by February 17\, 2022\, to save. \nWhy attend?\nWhether you join us in Seattle\, virtually\, or both\, you’ll find a seemingly endless lineup of top-tier education opportunities in every topic imaginable\, presented in an array of formats and offering all the valuable CME you need for the year. Don’t miss out on the most cutting-edge science covering every subspecialty and the opportunity to reconnect with friends and colleagues from around the world. View our safety and COVID-19 protocols. \nApril 2-7 | Seattle\, WA\nApril 24-26 | Virtual
URL:https://thebiocalendar.com/event/2022-aan-annual-meeting/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220331
DTEND;VALUE=DATE:20220401
DTSTAMP:20260514T015844
CREATED:20220129T000420Z
LAST-MODIFIED:20220129T000420Z
UID:2533-1648684800-1648771199@thebiocalendar.com
SUMMARY:The STAT Breakthrough Science Summit
DESCRIPTION:The 2022 STAT Breakthrough Science Summit will be a hybrid event. Purchase a Viewer Pass to join virtually. Apply for the Attendee Pass to access the event in-person. The in-person component will be hosted at the Apella event space located at 450 E 29th St\, New York\, NY.
URL:https://thebiocalendar.com/event/the-stat-breakthrough-science-summit/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220328T090000
DTEND;TZID=UTC:20220330T170000
DTSTAMP:20260514T015844
CREATED:20211229T202041Z
LAST-MODIFIED:20211229T202041Z
UID:2475-1648458000-1648659600@thebiocalendar.com
SUMMARY:Drug Discovery Webinar 2022
DESCRIPTION:After two successful editions of Drug Discovery Webinar 2021 during March and August 2021\, it is our greatest pleasure to welcome you to the 3rd Edition of Drug Discovery Webinar 2022 planned to be organized during March 28-30\, 2022. \nScholars Conferences heartily welcomes you all to the 3rd Edition of Scholars International Webinar on Drug Discovery and Development during and it mainly focus on the theme “Current Advancements in Drug Discovery and Development Process”. \nThe attending experts and industry partners will also provide a fantastic networking experience.\nDrug Discovery Webinar 2022 scientific program comprises Plenary talks\, Keynotes\, and Invited talks\, Oral presentations\, Workshops\, Symposiums\, YRF presentations\, multiple poster sessions\, sponsored luncheons\, and networking events for early-career and established scientists to establish connections across the globe.
URL:https://thebiocalendar.com/event/drug-discovery-webinar-2022/
LOCATION:PA
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2021/12/DDW-Logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220325T110000
DTEND;TZID=UTC:20220325T120000
DTSTAMP:20260514T015844
CREATED:20220311T032720Z
LAST-MODIFIED:20220311T032721Z
UID:2649-1648206000-1648209600@thebiocalendar.com
SUMMARY:Halloran Town Hall | Total Data Control and Custody: Moving from Excel to Complete Integration for Better Clinical Trial Decisions
DESCRIPTION:We have certainly come a long way in clinical trial operations over the past few years as our industry collectively shifted to decentralized and hybrid models to collect patient data outside of the traditional site model. And sponsors have a lot of data. This growth\, though celebrated\, also comes with growing pains\, like figuring how to build a large data mapping infrastructure to harness the trial’s data for better insight and oversight. \nIf you’re experiencing a similar issue\, please join our Halloran-hosted virtual Town Hall on March 25\, 2022\, from 11:00a.m. – 12:00p.m. EST on “Total Data Control and Custody: Moving from Excel to Complete Integration for Better Clinical Trial Decisions” led by the global data strategy and innovation team at CSL Behring and joined by experts from Halloran. CSL Behring has recently designed a data infrastructure for their studies that allowed their teams to have better control over their data\, leading to more informed decisions. They have major lessons learned and context behind their change and will be sharing their insights with the panel (and you!) to work through the following: \nHow do you integrate data sources and automate processes to get to a point of total data control regardless of company size?\nHow to get executive buy-in around data standards and oversight?\nWhat does the planning entail? Where do we start?\nIs this the future of data? How should companies prepare?\nIf you too want to evolve in this direction\, there is significant time and money that will need to be spent well in advance of when the trial data needs to be submitted. So\, let’s brainstorm and learn from each other. We hope you can join us – and bring your questions – to talk through scenarios for better data strategy\, control\, and custody for better decision making. \nMeet the Panel: \nMeghan Powers\, Director\, Clinical Practice Operations\, Halloran Consulting Group\nKaren Travers\, Associate Principal Consultant\, Organizational & Quality Solutions\, Halloran Consulting Group\nThomas Verish\, Head of Global Data Strategy & Innovation\, CSL Behring\nValerie Reynaert\, Head of Global Clinical Operations\, CSL Behring\nCharles Johnson\, Director\, eClinical Operations\, CSL Behring\nTony Ciliberto\, Senior Director\, Global Clinical Operations\, CSL Behring\nUpon registration you will receive a calendar invite with Zoom info. \nPlease feel free to distribute this event and any questions\, contact townhall@hallorancg.com.
URL:https://thebiocalendar.com/event/halloran-town-hall-total-data-control-and-custody-moving-from-excel-to-complete-integration-for-better-clinical-trial-decisions-2/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2022/03/3.25-Town-Hall-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220324T040000
DTEND;TZID=UTC:20220324T200000
DTSTAMP:20260514T015844
CREATED:20220305T001123Z
LAST-MODIFIED:20220305T001123Z
UID:2643-1648094400-1648152000@thebiocalendar.com
SUMMARY:Innovation in Maternal Health
DESCRIPTION:This event will feature a series of sessions\, discussions\, and panels examining racial disparities and inequities faced during pregnancy\, childbirth\, and postpartum through the lens of industry experts\, entrepreneurs\, innovators and those with lived experiences.  \n4:00- 5:00PM | Conversation Corner 1: Lived Experiences in Family Building\nBuilding a family can take many pathways. Whether male infertility or no male partner is part of that equation\, donor insemination can play a role. Join this conversation facilitated by Michelle Ottey\, Managing Director of CIC and consulting Director Laboratory Director at FairFax Cryobank\, that explores the lived experiences of family building.    \n4:00- 5:00PM | NIH Technology Accelerator Challenge for Maternal Health Info Session\nMaternal health is in crisis globally and here in the United States. Rates of maternal morbidity and mortality are higher in the U.S. than in any other developed nation\, with severe racial\, ethnic\, and socioeconomic disparities in maternal health outcomes persisting across the country. While there are many complex contributing factors and potential solutions\, new biomedical technologies have the potential to improve maternal health and reduce morbidity and mortality rates. The National Institutes of Health\, as part of the White House call to action to reduce pregnancy-related deaths and complications\, has issued multiple opportunities to support innovators developing maternal health technologies to address this crisis\, two of which will be presented at this session.  \n The NIH Technology Accelerator Challenge for Maternal Health is offering up to $1 million in cash prizes to spur and reward the development of prototypes for low-cost\, point-of-care molecular\, cellular\, and/or metabolic sensing and diagnostic technologies that could ultimately be used to diagnose and prevent the primary conditions associated with maternal morbidity and mortality. Additionally\, NIH is encouraging the small business and technology transfer communities to apply for grant funding to support the development and validation of various approaches\, technologies\, and tools\, including artificial intelligence and machine learning\, that indicate states of increased risk for and presence of maternal morbidity and mortality.  \nSpeakers:\nDr. Ilana Goldberg\, Program Director\nDr. C. Taylor Gilliland\, Senior Advisor for Innovation Programs\, Office of the Director at NIBIB  \n5:00- 6:00PM | Trend ThinkTank: Innovation to Decrease Maternal Mortality\nOver the past two decades\, the US has seen an increase in maternal mortality by 50-70. In Philadelphia\, the Maternal Mortality Review Committee’s 2020 Report highlighted that Non-Hispanic Black Women Represent 73% of Pregnancy-Related Deaths in Philadelphia.  \nAasta D. Mehta\, MD\, MPP\, Medical Officer of Women’s Health at the Philadelphia Department of Public Health\, and Director of the Philadelphia Maternal Mortality Program has called for collaborative\, innovative change: “In order to meaningfully reduce maternal mortality\, it is necessary to work collectively\, think outside the box and develop innovative solutions.”  We’ll explore how innovation can decrease the trend with our Trend ThinkTank Panelists.  \nThinkTank Panelists:\nModerator: Tif Wilson\, President & CEO of the Science Center\nJacquelyn Caglia\, Director of Learning\, Communications and U.S. Programs\, Merck for Mothers (confirmation in process)\nStefanie T. Modri\, RN\, MSN\, C-MNN\, co-founder of Vasowatch\nPanelist invitation pending  \n6:00- 7:00PM | Trend ThinkTank: Innovation to Support Maternal Mental Health\nMental health issues are the most common complications of pregnancy and childbirth\, affecting approximately 1 in 5 parents during pregnancy or the first year after being pregnant. Maternal Mental Health issues include a range of disorders and symptoms\, including but not limited to depression\, anxiety and psychosis. When left untreated these disorders can cause devastating consequences for the mother\, her baby\, her family and society.  \nThe good news is that risk for both depression and anxiety can be reduced and sometimes prevented\, and with treatment women can recover. This panel discussion focuses on some of the major causes of Maternal Mental Health issues and ways that innovators are working to address them.  \nThinkTank Panelists:\nDr. Jenny Starosta\, Clinical Psychologist\nKyana Brathwaite\, CEO of KB CALS\, Caring Advocacy & Services Liaison\nKirthika Parmeswaran\, CEO of Vital Start (confirmation in progress)\nSage Therapeutics\nModerator invitation pending  \n6:00- 7:00PM | Conversation Corner 2: Lived Experiences\nSmall group conversation with people sharing their lived experiences relating to maternal health. Led by Jenne Johns.  \n6:00- 8:00PM | Demo Tables Highlight Maternal Health Focused Start-Ups and Community Resources\nMeet startups and community organizations innovating in and transforming maternal health.\nPippy Sips\nVital Start\nLia Diagnostics\nVasowatch\nMaternity Care Coalition/MOMmobile\nMotherButter\nZawadi Doula Services\nThe Priceless Woman and Magic Vsteam  \n7:00- 8:00PM | Futures Lab: Maternal Health in 2050\nJoin us for a special workshop session where we will brainstorm and investigate potential futures in maternal health. Why should we design for the future? Futures thinking isn’t meant to make any predictions\, but rather reveal the many possible and probable futures that could be. This type of thinking exercise allows us to examine the implications of present-day issues to gain new perspectives and context for decision making strategies.
URL:https://thebiocalendar.com/event/innovation-in-maternal-health/
LOCATION:CA\, United States
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2022/03/SCLogo_Final-blkLetters_NEWcolor.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220323T160000
DTEND;TZID=UTC:20220323T190000
DTSTAMP:20260514T015844
CREATED:20220308T102736Z
LAST-MODIFIED:20220308T102739Z
UID:2645-1648051200-1648062000@thebiocalendar.com
SUMMARY:The NIH as a Technology Development and Commercialization Partner
DESCRIPTION:BioXchange is excited to host the NIH this month as they discuss how they can be a technology development and commercialization partner for life science companies. The discussion will be followed by live networking on Grapevine Network. \nThe National Institutes of Health (NIH) is the world’s largest basic science research institute in the world. Our extramural program represents the biggest funder of basic and clinical research to universities and other research centers. Those funds\, as well as research done on the NIH campus by our own faculty\, make possible important discoveries every day about the fundamental nature of living things. The NIH Hospital is the largest center dedicated to clinical investigation. The NIH fosters innovation in the commercial sector via our Small Business Innovative Research (SBIR) Program. Our mission includes improving public health for the global community. \nAll these statements are true. But\, if this is all you know about NIH\, then you don’t really know NIH. \nMuch less known is the part of our mission devoted to facilitating economic developing. We’re not just a top tier place for academics to move research forward alongside a key opinion leader\, leading to a publication in esteemed journal or promising grant proposal. On the contrary\, the NIH has established itself as open for business – as one of the go-to places for the healthcare industry to work with a thought-leader\, overcome a technology or knowledge gap\, and get their products to market. Across 27 Institutes and Centers\, we cover nearly every disease and disorder imaginable – and marketable. We are the largest provider of in-kind support in the world. Research tools – mice\, cell lines\, antibodies – are provided at little or no cost. Sure\, we develop drugs – but we also develop devices\, diagnostics\, wearable and digital health solutions\, and software. \nWe are competitive on the business/financial front regarding equity\, royalty costs\, and overhead rates. We need those in the commercial sector to fulfill our mission of accelerating and promoting economic development. That means working with companies to positively impact your chances as an equity investment\, a M&A target\, an active employer. The NIH might not be the first place you seek out to bolster your pipeline or accelerate technology development – but perhaps we should be. \nSuggested take-aways & learning points:\nThe National Institutes of Health (NIH) as a Technology Development and Commercialization Partner \nThe National Institutes of Health (NIH) is a resource that companies should consider to bolster their pipeline or solve a development problem. Attendees will learn: \n• Who we are. The NIH is more than basic research and SBIRs. Technology commercialization and economic development is part of our mission. \n• That companies\, entrepreneurs\, and other buy-side stakeholders – not just academia – can partner with the NIH \n• Why industry partnerships are mutually beneficial for companies and the NIH \n• How companies have worked with the NIH (success stories and partnership examples) \n• Next steps – points of contact\, partnering mechanisms\, licensing \n***Event is expected to sell out and NOT ALL RVSPS ARE GUARANTEED ENTRY into the event due to the limited attendee capacity offered on the platform.
URL:https://thebiocalendar.com/event/the-nih-as-a-technology-development-and-commercialization-partner/
LOCATION:PA
ATTACH;FMTTYPE=image/gif:https://thebiocalendar.com/wp-content/uploads/2022/03/Copy-of-Purple-Zodiac-Sign-Animated-Presentation.gif
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220322
DTEND;VALUE=DATE:20220325
DTSTAMP:20260514T015844
CREATED:20220126T203613Z
LAST-MODIFIED:20220126T203817Z
UID:2524-1647907200-1648166399@thebiocalendar.com
SUMMARY:Digital RESI
DESCRIPTION:The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain\, connecting start-ups with 10 categories of global investors across the silos of drugs\, devices\, diagnostics and digital health (4 Ds). RESI caters to both the earliest stage start-ups\, those seeking grants\, seed and angel capital\, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare. \n\n\n\n\n\n\nRESI Conference Series 2022 \n\nDigital RESI JPM\, January 11-13\nDigital RESI\, March 22-24\nRESI San Diego\, June 14-16\nRESI Boston\, September 20-22\nRESI Asia\, November 15-17
URL:https://thebiocalendar.com/event/digital-resi/
LOCATION:PA
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2021/06/RESI_Logo_square.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220322
DTEND;VALUE=DATE:20220324
DTSTAMP:20260514T015844
CREATED:20211112T223713Z
LAST-MODIFIED:20211112T223713Z
UID:2390-1647907200-1648079999@thebiocalendar.com
SUMMARY:5th Annual Neuroscience Innovation Forum
DESCRIPTION:Following the success of this year’s digital event\, we are pleased to announce that our 5th Annual Neuroscience Innovation Forum (NIF) will take place on the 22nd – 23rd of March 2022. The organisers have decided again\, due to the pandemic\, to host the 5th NIF in a solely digital format. This allows us to further support our community and past attendees. We will provide both the usual stimulating program and networking opportunities through our online video and audio meeting system. \nThe main programme for the 5th Annual NIF will be spread throughout 2 days. Featuring more than 12 hours of high-level keynotes\, panel discussions\, and spotlight showcases. The target audience for this event are buy and sell-side analysts from investment banks and funds\, as well as partnering executives from pharma\, biotech\, digital therapeutics and neurotech companies. We anticipate 300+ delegates and 35+ company presentations by established listed\, private and growth companies.
URL:https://thebiocalendar.com/event/5th-annual-neuroscience-innovation-forum/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220321T090000
DTEND;TZID=UTC:20220321T101500
DTSTAMP:20260514T015844
CREATED:20220211T012442Z
LAST-MODIFIED:20220211T012442Z
UID:2581-1647853200-1647857700@thebiocalendar.com
SUMMARY:The Art of Women Thriving in STEM
DESCRIPTION:90 DAY COURSE – THE ART OF WOMEN THRIVING IN STEM:\nTo help women get their MoJo back and address stress at the CORE.  \nOur program addresses:\nManaging Emotions\, Perfectionism\, Imposter Syndrome\, Limiting Beliefs\, Burnout\, Anxiety\, Procrastination\, Fear\, Judgement\, Lack of passion\, Lack of confidence \nTransformational Result Examples:\nHappier You\nLife-Work Balance\nGreater Recognition\nMore Confidence\nImproved Relationship\nRenewed Passion\nCareer Advancement\nIncreased Pay\nNew Job\nLove For Your Work and Life \nThe sessions will be scheduled for 75 minutes once a week based on the availability of the majority of the group doing the workshop.
URL:https://thebiocalendar.com/event/the-art-of-women-thriving-in-stem-2/2022-03-21/
LOCATION:PA
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2022/02/The-Art-of-Women-Thriving-in-STEM-Flyer-March-2022.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220320
DTEND;VALUE=DATE:20220325
DTSTAMP:20260514T015844
CREATED:20211106T201343Z
LAST-MODIFIED:20211106T201343Z
UID:2368-1647734400-1648166399@thebiocalendar.com
SUMMARY:ACS Spring 2022
DESCRIPTION:Hybrid Registration\n\n\n\n\n\n\n\nEnjoy all that San Diego has to offer in March\nAttend both in-person only and live hybrid sessions\nLive in-session Q&A opportunities\nIn-person networking opportunities\nFull access to all in-person\, virtual\, and on-demand sessions included in your full registration\n24/7 access to programming; on-demand content available up to 30 days post event\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nVirtual Registration\n\n\n\n\n\n\n\nAttend live hybrid and 100% live virtual sessions via the meeting platform\n24/7 access to programming; on-demand content available up to 30 days post event\nInteractive sessions with live chats and Q&A\nDigital networking opportunities to connect with others without leaving your home
URL:https://thebiocalendar.com/event/acs-spring-2022/
LOCATION:PA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220317T170000
DTEND;TZID=UTC:20220317T190000
DTSTAMP:20260514T015844
CREATED:20220217T041937Z
LAST-MODIFIED:20220217T041937Z
UID:2627-1647536400-1647543600@thebiocalendar.com
SUMMARY:Bio on the Bay
DESCRIPTION:A bit of malarkey and lots of green beer\, make no mistake you’ll want to be here. Join CLS and Lonza for our annual Bio on the Bay\, an informal networking event for the life sciences community. \nThis event is closed to service provider companies that are not members of California Life Sciences. To become a member\, click here. \nTo ensure a safe and enjoyable experience for everyone\, please review our event safety protocols prior to the event.
URL:https://thebiocalendar.com/event/bio-on-the-bay/
LOCATION:PA
END:VEVENT
END:VCALENDAR